Novartis Ag (NVS) Cash from Investing Activities Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
-78.48% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-32.26% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-4.78% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-62.97% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-36.21% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
60.61% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-38.13% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
14.56% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
42.22% |
| Dec 31, 2024 |
-40.64% |
| Sep 30, 2024 |
32.79% |
| Jun 30, 2024 |
-227.30% |
| Jun 30, 2023 |
-35.32% |
| Jun 30, 2022 |
-190.56% |
| Dec 31, 2021 |
49.41% |
| Sep 30, 2021 |
-11.62% |
| Jun 30, 2021 |
-71.80% |
| Dec 31, 2020 |
16.93% |
| Jun 30, 2020 |
-8.04% |
| Dec 31, 2019 |
33.43% |
| Jun 30, 2019 |
7.19% |
| Sep 30, 2018 |
-13.06% |
| Dec 31, 2017 |
-10,716.70% |
| Sep 30, 2017 |
-23,221.99% |
| Jun 30, 2017 |
-7,469.54% |
| Dec 31, 2016 |
-24,630.44% |
| Sep 30, 2016 |
-9,608.26% |
| Jun 30, 2016 |
-9,860.96% |
| Mar 31, 2016 |
-9,223.03% |
| Dec 31, 2014 |
1.52% |
| Sep 30, 2014 |
27.95% |
| Jun 30, 2014 |
-108.50% |
| Dec 31, 2013 |
27.96% |
| Mar 31, 2013 |
37.73% |
| Mar 31, 2012 |
46.10% |
